Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence D Mayer

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
International Journal of Nanomedicine|June 20, 2019
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake propertiesLawrence D Mayer, Paul Tardi, Arthur C Louie
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumventionTroy O Harasym, Barry D Liboiron, Lawrence D Mayer
Journal of Pharmaceutical Sciences|November 15, 2008
Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouseWilliam F Bayne, Lawrence D Mayer, Christine E Swenson
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2002
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipidsWai Ming Li, Lawrence D Mayer, Marcel B Bally
Journal of Experimental Therapeutics & Oncology|June 26, 2003
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient miceDaniel E Lopes de Menezes, Yanping Hu, Lawrence D Mayer
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 7, 2002
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systemsJennifer A Shabbits, Gigi N C Chiu, Lawrence D Mayer
Biochimica Et Biophysica Acta|July 2, 2003
Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesisGigi N C Chiu, Marcel B Bally, Lawrence D Mayer
Biochimica Et Biophysica Acta|April 18, 2002
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipidsGigi N C Chiu, Marcel B Bally, Lawrence D Mayer
Biochimica Et Biophysica Acta|April 1, 2006
Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transitionLudger M Ickenstein, Maria C Sandström, Lawrence D Mayer, et al.
Biochimica Et Biophysica Acta|March 28, 2003
Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumorsVincent W H Fung, Gigi N C Chiu, Lawrence D Mayer
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
International Journal of Nanomedicine|June 20, 2019
CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake propertiesLawrence D Mayer, Paul Tardi, Arthur C Louie
Methods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumventionTroy O Harasym, Barry D Liboiron, Lawrence D Mayer
Journal of Pharmaceutical Sciences|November 15, 2008
Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouseWilliam F Bayne, Lawrence D Mayer, Christine E Swenson
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2002
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipidsWai Ming Li, Lawrence D Mayer, Marcel B Bally
Journal of Experimental Therapeutics & Oncology|June 26, 2003
Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient miceDaniel E Lopes de Menezes, Yanping Hu, Lawrence D Mayer
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 7, 2002
Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systemsJennifer A Shabbits, Gigi N C Chiu, Lawrence D Mayer
Biochimica Et Biophysica Acta|July 2, 2003
Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesisGigi N C Chiu, Marcel B Bally, Lawrence D Mayer
Biochimica Et Biophysica Acta|April 18, 2002
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipidsGigi N C Chiu, Marcel B Bally, Lawrence D Mayer
Biochimica Et Biophysica Acta|April 1, 2006
Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transitionLudger M Ickenstein, Maria C Sandström, Lawrence D Mayer, et al.
Biochimica Et Biophysica Acta|March 28, 2003
Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumorsVincent W H Fung, Gigi N C Chiu, Lawrence D Mayer
Pageof 6